Symbol="ATRA"
AssetType="Common Stock"
Name="Atara Biotherapeutics Inc"
Description="Atara Biotherapeutics, Inc., a commercially available T-cell immunotherapy company, develops treatments for cancer patients, autoimmune and viral diseases in the United States. The company is headquartered in South San Francisco, California."
CIK="1604464"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="180759000"
EBITDA="-256026000"
PERatio="None"
PEGRatio="0"
BookValue="0.673"
DividendPerShare="0"
DividendYield="0"
EPS="-1.97"
RevenuePerShareTTM="0.559"
ProfitMargin="0"
OperatingMarginTTM="-4.546"
ReturnOnAssetsTTM="-0.467"
ReturnOnEquityTTM="-1.486"
RevenueTTM="57485000"
GrossProfitTTM="63573000"
DilutedEPSTTM="-1.97"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.832"
AnalystTargetPrice="16.27"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="4.538"
PriceToBookRatio="1.967"
EVToRevenue="2.31"
EVToEBITDA="-0.562"
Beta="0.944"
num_52WeekHigh="5.94"
num_52WeekLow="1.45"
num_50DayMovingAverage="1.875"
num_200DayMovingAverage="3.29"
SharesOutstanding="97972000"
DividendDate="None"
ExDividendDate="None"
symbol="ATRA"
open="1.84"
high="2.08"
low="1.83"
price="2.06"
volume="1862728.00"
latest_trading_day="2023-07-28"
previous_close="1.79"
change="0.27"
change_percent="15.0838%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="97"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="3"
Volume_recent_avg="1719125"
Change_recent_avg="-0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.67"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="3"
Aroon_momentum_negative="97"
image_negative_thumbnail_id_1="1162"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0196.jpeg"
image_negative_thumbnail_id_2="1120"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0153.jpeg"
image_neutral_thumbnail_id_1="531"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0068.jpeg"
image_neutral_thumbnail_id_2="571"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0028.jpeg"
image_positive_thumbnail_id_1="685"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0023.jpeg"
image_positive_thumbnail_id_2="645"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0063.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1167"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0001.jpeg"
